News
-
-
PRESS RELEASE
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provide overview of recent corporate and clinical advancements, with upcoming milestones including merger closing and clinical trial commencement -
-
PRESS RELEASE
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA and Kintara announce positive results from TuHURA's Phase 1b trial evaluating IFx-2.0 in ICI naïve patients with advanced MCC and cSCC, overcoming resistance to ICI therapy. Data presented at 2024 ASCO Annual Meeting -
-
PRESS RELEASE
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA and Kintara announce merger for advancing late-stage oncology pipeline with focus on personalized cancer vaccines and bi-functional ADCs. $31 million funding secured for operations till late 2025. Joint conference call scheduled for April 3, 2024 -
PRESS RELEASE
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development
TuHURA Biosciences, Inc. appoints Dr. Dennis Yamashita as Chief Scientific Officer and Head of Discovery Research and Early Development to advance novel personalized cancer vaccines and bi-functional antibody drug conjugates. Dr. Yamashita brings over 30 years of experience in R&D drug discovery and development
